Description: Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19 patient triage; and a research and development agreement with Naval Medical Research Center to develop lateral flow rapid test for diagnosis of various tick-borne diseases, including Lyme disease. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Home Page: www.bluejaydx.com
BJDX Technical Analysis
360 Massachusetts Avenue
Acton,
MA
01720
United States
Phone:
844 327 7078
Officers
| Name | Title |
|---|---|
| Mr. Indranil Dey | Pres, CEO & Director |
| Dr. Jason Cook | Chief Technology Officer |
| Mr. Kenneth R. Fisher CPA | Chief Financial Officer |
| Mr. Kevin Vance | Chief Commercial Officer |
| Mark W. Feinberg | Chief Medical Advisor |
| Dr. Mark W. Feinberg M.D. | Chief Medical Advisor |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6712 |
| Price-to-Sales TTM: | 34.8037 |
| IPO Date: | 2021-11-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |